Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer
Status:
Recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
Prostate cancer is the second most common cancer among Canadian men of which approximately
20-30% present with high-risk tumour characteristic.
Although surgery can be curative in patients evidencing pathological high-risk disease
(extracapsular extension, seminal vesicle involvement, positive surgical margins), a large
proportion will develop biochemical failure within years from the surgical procedure. The
failure rate is even more pronounced in those patients that present with high prostate
specific antigen (PSA) levels, pT3 disease, positive margins and Gleason score ≥8 with an
estimated 75% failure rate at 10 years.
Post-operative radiotherapy (RT) has been shown in three randomized trials to significantly
decrease the biochemical failure rate and in one of the trials a survival benefit was also
seen with the addition of post-operative RT and is considered by many investigators standard
therapy in patients with pathological high-risks factors even in absence of biochemical
failure.
Phase:
Phase 2
Details
Lead Sponsor:
Luis Souhami McGill University Health Centre/Research Institute of the McGill University Health Centre